RxDoctor Payments Data

Frances Deadmond, PA

Medical · Effingham, ILNPI 1255787263

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $7,272 of the $8,890 with a category attached, or 81.8%. It is spread thinly across 19 manufacturers, the largest accounting for just 20.2% — the pattern of someone who eats at a lot of different presentations. Among medical clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$8,890in general payments, 2019–2025

Across 454 payments — averaging $19.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Regeneron Healthcare Solutions, Inc.$2K
  • Amgen$1K
  • Lilly USA, LLC$861
  • Johnson & Johnson$558
  • Dermavant Sciences, Inc.$548
  • plus $2K from 13 others

What the payments were for

  • Consulting fees$1,09412%
  • Food & beverage$7,27282%
  • Education$5256%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,890 in reported general payments places this provider in the 95th percentile of 449 medical providers in Illinois.

See all medical providers in Illinois

Medicare billing

Part B allowed, 2024
$214,966
Medicare patients
847
Services billed
5,634

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Taltz AutoinjectorIxekizumab29$211,473
OtezlaApremilast46$208,626
Cosentyx Unoready PenSecukinumab16$150,332
Dupixent SyringeDupilumab23$106,041
Dupixent PenDupilumab16$80,938
AdbryTralokinumab-Ldrm22$78,531
Betamethasone Dipropionate128$3,080
Clobetasol Propionate44$2,213
Fluorouracil27$2,063
Tacrolimus15$1,200
Triamcinolone Acetonide180$1,195
Metronidazole18$1,131
Doxycycline Hyclate82$1,121
Ciclopirox25$973
Mupirocin97$686

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$1,357$208,62646 claims
LEO Pharma Inc.Adbry$203$78,53122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 449 medical providers in Illinois.

Other medical in Effingham

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →